Hib-hepatitis B vaccine - Merck & Co

Drug Profile

Hib-hepatitis B vaccine - Merck & Co

Alternative Names: Comvax

Latest Information Update: 30 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer CSL; Merck & Co
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Haemophilus infections; Hepatitis B

Most Recent Events

  • 30 Oct 2000 CSL has licensed Comvax® in Australia
  • 13 Oct 2000 Registered for Haemophilus infections in Australia (IM)
  • 13 Oct 2000 Registered for Hepatitis B in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top